Ligand-activated Ahr signaling leads to disruption of nephrogenesis and altered Wilms' tumor suppressor mRNA splicing

Oncogene

Volumn 22, Issue 14, 2003, Pages 2160-2171

  Falahatpisheh, M Hadi ^a   Ramos, Kenneth S ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Ahr; Nephrogenesis; WT1 splicing

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; DIMETHYL SULFOXIDE; WT1 PROTEIN;

ALTERNATIVE RNA SPLICING; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; EPITHELIZATION; GLOMERULUS BASEMENT MEMBRANE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; INHIBITION KINETICS; KIDNEY DEVELOPMENT; KIDNEY INTERSTITIUM; MOLECULAR MECHANICS; MOUSE; NEPHROBLASTOMA; NONHUMAN; ORGAN CULTURE; PODOCYTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANIMALS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; KIDNEY; LIGANDS; MICE; MORPHOGENESIS; ORGAN CULTURE TECHNIQUES; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; WT1 PROTEINS;

ANIMALIA; GLOMERULUS; MAMMALIA; MURINAE;

EID: 0038636447     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206238     Document Type: Article

References (47)

1. Abbott BD. (1995). Toxicology, 105, 365-373.
2. Aswin M, Lasley M, Micholas DH and Andreas S. (1998). Kidney Int., 53, 1512-1518.
3. Avner ED. (1993). Sem. Nephrol., 13, 427-435.
4. Avner ED and Sweeney WE. (1990). Pediatr. Nephrol., 4, 372-377.
5. Barbaux S, Niaudet P, Gubler MC, Grunfeld JP, Jaubert F, Kuttern F, Fekete CN, Souleyreau-Theville N, Thibaud E, Fellous M and McElreavey K. (1997). Nat. Genet., 17, 467-470.
6. Bowes RC, Parrish AR, Steinberg MA, Willet KL, Zhao W, Savas U, Jefcoate CR, Safe SH and Ramos KS (1996). Biochem. Pharmacol., 52, 587-595.
7. Bowes RC and Ramos KS (1994). Toxicol. In Vitro, 8, 1151-1160.
8. Bradford MM. (1976). Anal. Biochem., 72, 248-254.
9. Bruening W and Pelletier J. (1996). J. Biol. Chem., 271, 8646-8654.
10. Cantrell SM, Joy-Schlezinger J, Stegeman JJ, Tillitt DE and Hannink M. (1997). Toxicol. Appl. Pharmacol., 148, 24-34.
11. Carver LA and Bradfield CA. (1997). J. Biol. Chem., 272, 11452-11456.
12. Crews ST and Fan CM. (1999). Curr. Opion. Gen. Dev., 9, 580-587.
13. Dressler GR. (1997). Adv. Nephrol. Necker Hosp., 26, 1-17.
14. Drumond IA, Madden SL, Rohwer NP, Bell GI, Suklhatme VP and Rauscher FI. (1992). Science, 257, 674-678.
15. Gessler M, Konig A and Bruns GA. (1992). Genomics, 12, 807-813.
16. Gutierrez A, Khan ZU, Miralles CP, Mehta AK, Ruano D, Araujo F, Victorica J and De Blas AL. (1997). Mol. Brain Res., 45, 59-70.
17. Haber DA, Sohn RL, Bucker AJ, Pelletier J, Call KM and Housman DE. (1991). Proc. Natl. Acad. Sci. USA, 88, 9618-9622.
18. Habib R, Loirat C, Gubler MC, Niaudet P, Bensam A, Levy M and Broyer M. (1985). Clin. Nephrol., 24, 269-278.
19. Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, Siegler U, Gubler MC and Schedl A. (2001). Cell, 106, 319-329.
20. Hewitt SM and Saunders GF. (1996). Anticancer Res., 16, 621-626.
21. Hida M, Omori S and Awazu M. (2002). Kidney Int., 61, 1252-1262.
22. Hundeiker C, Pineau T, Gassar G, Betensky RA, Gleichmann E and Esser C. (1999). Int. J. Immunopharmacol., 21, 841-859.
23. Hushka LJ, Williams JS and Greenlee WF. (1998). Toxicol. Appl. Pharmacol., 152, 200-210.
24. Kafafi SA, Afeefy HY, Said HK and Kafafi AG. (1993). Chem. Res. Toxicol., 6, 328-334.
25. Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH and Sonenshein GE. (2000). Oncogene, 19, 5498-5506.
26. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D and Jaenisch R. (1993). Cell, 74, 679-691.
27. Kudoh T, Ishidate T, Nakamura T, Toyoshima K and Akiyama T. (1996). Oncogene, 13, 1431-1439.
28. Lahvis GP, Lindell SL, Thomas RS, McCluskey RS, Murphy C, Glover E, Bentz M, Southard J and Bradfield CA. (2000). Proc. Natl. Acad. Sci. USA, 97, 10442-10447.
29. Laity JH, Chung J, Dyson J and Wright PE. (2000). Biochemistry, 39, 5341-5348.
30. Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, Heyningen V and Hastie ND. (1995). Cell, 81, 391-401.
31. Nebert DW. (1994). Biochem. Pharmacol. 47, 25-37.
32. Peters JM, Narotsky MG, Elizondo G, Fernandez-Salguero PM, Gonzalez FJ and Abbott BD. (1999). Toxicol. Sci., 47, 86-92.
33. Peterson RE, Theobald HM and Kimmel GL. (1993). Crit. Rev. Toxicol., 23, 283-337.
34. Pritchard-Jones K, Flering S, Davidson D, Bickmore W, Porteus D, Gosden C, Bard J, Buckler A, Pelletier J and Housman D. (1990). Nature, 346, 194-197.
35. Renshaw J, King-Underwood L and Pritchard-Jones K. (1997). Genes Chrom. Cancer, 19, 256-266.
36. Ryan G, Steelepperkins V, Morris JF, Rauscher FJ and Dressler GR. (1995). Development, 121, 867-875.
37. Saxon L. (ed). (1987). Organogenesis of the Kidney. Cambridge University Press: Cambridge, UK.
38. Scharnhorst V, Deker P, Vander-EB AJ and Jochemsen AG. (1999). J. Biol. Chem., 274, 23456-23462.
39. Scharnhorst V, Kranenburg O, Van Der EB AJ and Jochemsen AG. (1997). Cell Growth Differ., 8, 133-143.
40. Schmidt JV, Huei-Ting Su GH, Reddy JK, Simon MC and Bradfield CA. (1996). Proc. Natl. Acad. Sci. USA, 93, 6731-6736.
41. Sharma PM, Bowman M, Madden SL, Rauscher FJ and Sukumar S. (1994). Genes Dev., 8, 720-731.
42. Toth T and Takebayashi S. (1996). Nephron, 74, 64-71.
43. Walker C, Rutten F, Yuan X, Pass H, Mew DM and Everitt J. (1994). Cancer Res., 54, 3101-3106.
44. Wang ZY, Masdden SL, Deuel TF and Rauscher FI. (1992). J. Biol. Chem., 267, 21999-22002.
45. Winn LM and Wells PG. (1997). Free Rod. Biol. Med., 22, 607-621.
46. Yeger H, Forget D, Alami J and Williams B. (1996). In Vitro Cell Dev. Biol., 32, 496-504.
47. Zaher H, Fernandez-Salguero PM, Letterio J, Sheikh MS, Fornace AJ, Roberts AB and Gonzalez FJ. (1998). Mol. Pharmacol., 54, 313-321.